[BLRX] BioLineRx Ltd.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 46.83 M

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 0.98 Change: 0 (0%)
Ext. hours: Change: 0 (0%)

chart BLRX

Refresh chart

Strongest Trends Summary For BLRX

BLRX is in the medium-term down -58% below S&P in 1 year.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: BioLineRx Ltd., a clinical stage biopharmaceutical development company, is engaged in identifying, in-licensing, and developing therapeutic candidates that address unmet medical needs. The company?s development pipeline consists of clinical-stage therapeutic candidates, including BL-1040, a resorbable polymer solution being developed to reduce or prevent the ventricular remodeling; BL-8040, a peptide for the treatment of acute myeloid leukemia, stem cell mobilization, and other hematological indications; BL-7010, a polymer for the treatment of celiac disease; BL-5010, which is being developed as a medical device for the non-surgical removal of benign skin lesions; BL-7040, an oligonucleotide for the treatment of inflammatory bowel disease; and BL-8020, an orally available treatment for the Hepatitis C virus and other viral indications. It also has three therapeutic candidates in the preclinical stages of development, such as BL-8030 for the treatment of Hepatitis C; BL-9010 to treat severe allergies/asthma; a

Fundamental Ratios
Shares Outstanding56.42 M EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV0.39 Price/Cash Per Share
Price/Free Cash Flow-3.12 ROA-10.2% ROE-13.77% ROI
Current Ratio3.57 Quick Ratio Long Term Debt/Equity Debt Ratio0.35
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities Cash From Investing Activities25.78 M Cash From Operating Activities8.14 M Gross Profit
Net Profit-22.31 M Operating Profit Total Assets159.17 M Total Current Assets147.05 M
Total Current Liabilities41.23 M Total Debt Total Liabilities41.23 M Total Revenue
Technical Data
High 52 week6.92 Low 52 week0.4 Last close2.68 Last change-0.74%
RSI50.55 Average true range0.15 Beta0.6 Volume46.18 K
Simple moving average 20 days-2.39% Simple moving average 50 days-7.55% Simple moving average 200 days-30.21%
Performance Data
Performance Week-2.55% Performance Month-7.59% Performance Quart-37.38% Performance Half-55.4%
Performance Year103.03% Performance Year-to-date512.85% Volatility daily2.97% Volatility weekly6.65%
Volatility monthly13.63% Volatility yearly47.2% Relative Volume117.29% Average Volume58.61 K
New High New Low

News

2020-06-04 19:23:48 | Is Bioline RX Ltd BLRX Going to Burn These Hedge Funds?

2020-06-01 08:00:00 | BioLineRx Announces $4.39 Million Registered Direct Offering

2020-05-29 11:46:03 | Top Ranked Momentum Stocks to Buy for May 29th

2020-05-27 09:49:57 | 3 “Strong Buy” Biotech Stocks Under $5 With Explosive Upside Potential

2020-05-27 07:00:00 | BioLineRx Announces Publication of Data from Ongoing COMBAT/KEYNOTE-202 Clinical Trial in Nature Medicine

2020-05-26 08:40:00 | BioLineRx Announces $9.0 Million Registered Direct Offering

2020-05-20 08:00:00 | BioLineRx Ltd. to Host Earnings Call

2020-05-20 07:00:00 | BioLineRx Reports First Quarter 2020 Financial Results and Provides Corporate Update

2020-05-15 07:00:00 | BioLineRx to Report First Quarter 2020 Results on May 20, 2020

2020-03-12 08:00:00 | BioLineRx Ltd. to Host Earnings Call

2020-03-12 07:00:00 | BioLineRx Reports Year-End 2019 Financial Results and Provides Corporate Update

2020-03-06 08:00:00 | BioLineRx to Report Annual 2019 Results on March 12, 2020

2020-02-27 07:43:00 | BioLineRx Announces Notice of Allowance from USPTO for Patent Covering Motixafortide BL-8040 in Combination With Anti-PD-1 for the Treatment of Any Type of Cancer

2020-01-23 11:01:04 | BioLineRx Concludes Recruitment in Pancreatic Cancer Study

2020-01-22 07:00:00 | BioLineRx Completes Recruitment in Triple Combination Arm of COMBAT/KEYNOTE-202 Study in Patients With Second-line Metastatic Pancreatic Cancer

2020-01-15 09:56:02 | BioLineRx's Pancreatic Cancer Drug Gets Orphan Drug Tag in EU

2020-01-14 07:46:48 | BioLineRx Receives Orphan Drug Designation for Motixafortide BL-8040 for the Treatment of Pancreatic Cancer in Europe

2020-01-08 07:00:00 | BioLineRx to Present at the 2020 Biotech Showcase

2019-12-13 07:00:00 | BioLineRx Announces Updated Phase 2a Data From Triple Combination Arm of COMBAT/KEYNOTE-202 Study in Patients With Second-line Metastatic Pancreatic Cancer

2019-12-06 07:39:38 | The Daily Biotech Pulse: Cassava Gains On Alzheimer's Presentation, Bristol-Myers Hikes Dividend

2019-12-05 07:00:00 | BioLineRx Announces Preliminary Phase 2a Data from Triple Combination Arm of COMBAT/KEYNOTE-202 Study in Second Line Patients With Metastatic Pancreatic Cancer

2019-11-26 07:00:00 | BioLineRx to Host Investor and Analyst Breakfast Meeting on December 5, 2019 in New York

2019-11-11 07:00:00 | BioLineRx Reports Third Quarter 2019 Financial Results and Provides Corporate Update

2019-11-06 07:00:00 | BioLineRx to Report Third Quarter 2019 Results on November 11, 2019

2019-11-05 09:00:00 | BioLineRx Announces BL-8040 in Combination With KEYTRUDA Shows Clinical Activity in Heavily Pretreated Metastatic Pancreatic Cancer Patients

2019-11-05 08:00:00 | BioLineRx Presents Preclinical Data From Triple Combination of BL-8040, Anti PD-1 and Chemotherapy Demonstrating Significant Reduction in Pancreatic Tumor Growth and Favorable Changes in Tumor Microenvironment

2019-10-31 07:00:00 | BioLineRx to Present Two Posters at the Society for Immunotherapy of Cancer SITC 2019

2019-10-29 07:00:00 | BioLineRx to Deliver Oral Presentation at ESMO Immuno-Oncology Congress 2019

2019-09-26 09:00:01 | BioLineRx Begins Part 2 of Phase I/IIa Study on Solid Tumors

2019-09-25 07:00:00 | BioLineRx Announces Dosing of First Patient in Part 2 of Phase 1/2a Clinical Study for AGI-134, a Novel Immunotherapy for Treatment of Solid Tumors

2019-09-04 07:08:03 | The Daily Biotech Pulse: Puma Leaps, Aerie Borrows, Hepion Back In Nasdaq's Good Books

2019-09-03 07:00:00 | BioLineRx Successfully Completes Dose-Escalation Part of Phase 1/2a Clinical Study for AGI-134, a Novel Immunotherapy for Treatment of Solid Tumors

2019-08-06 07:00:00 | BioLineRx Reports Second Quarter 2019 Financial Results and Provides Corporate Update

2019-08-02 11:25:03 | Tenet Healthcare THC Q2 Earnings: What's in the Cards?

2019-07-30 08:00:00 | BioLineRx to Report Second Quarter 2019 Results on August 6, 2019

2019-06-28 16:01:00 | BioLineRx Announces Change in Ratio of American Depositary Shares to Ordinary Shares

2019-06-13 07:00:00 | BioLineRx to Present at the JMP Securities 2019 Life Sciences Conference

2019-05-17 09:00:01 | BioLineRx BLRX Moves to Buy: Rationale Behind the Upgrade

2019-05-14 07:00:00 | BioLineRx Reports First Quarter 2019 Financial Results and Provides Corporate Update

2019-05-07 08:00:00 | BioLineRx to Report First Quarter 2019 Results on May 14, 2019

2019-05-07 07:00:00 | BioLineRx Announces FDA Approval of IND Application for AGI-134, a Novel Immunotherapy Anti-Cancer Vaccine for Solid Tumors

2019-05-01 08:10:00 | Biotech News, What Milestones and Catalysts Could Drive BioLineRx Shares in 2019

2019-03-28 07:00:00 | BioLineRx Reports Year End 2018 Financial Results and Provides Corporate Update

2019-03-27 15:00:00 | Four Tech Stocks Sparking Activity on Wednesday

2019-03-27 07:00:00 | BioLineRx Announces Successful Engraftment Data From Phase 3 GENESIS Trial for BL-8040 in Multiple Myeloma Patients

2019-03-21 08:00:00 | BioLineRx to Report Annual 2018 Results on March 28, 2019

2019-03-14 07:00:00 | BioLineRx to Present at the 29th Annual Oppenheimer Healthcare Conference

2019-02-07 13:42:00 | BioLineRx Announces Closing of $15.4 Million Underwritten Public Offering of its American Depositary Shares and Warrants

2019-02-05 11:40:00 | BioLineRx Announces Pricing of $15.4 Million Underwritten Public Offering of its American Depositary Shares and Warrants

2019-02-05 10:30:00 | Biotech on the Brink of Breaking Out